Z. Sun

发表

Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.

R. Gelber, B. Gusterson, A. Goldhirsch, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181.

C. Lovly, M. Harkenrider, N. Pennell, 2022, Clinical lung cancer.

A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial

J. Bernhard, M. Regan, U. Hasler-Strub, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma

J. Yu, X. Zhang, Jian Li, 2016, Clinical and Translational Oncology.

Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial.

J. Bernhard, F. Cardoso, A. Thompson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized trial of anthracycline dose intensification during induction of younger patients with acute myeloid leukemia: Results of Eastern Cooperative Oncology Group study E1900.

M. Tallman, G. Dewald, H. Lazarus, 2009, Journal of Clinical Oncology.

Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.

R. Gelber, B. Gusterson, A. Goldhirsch, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy benefit for 'ER-positive' breast cancer and contamination of nonluminal subtypes—waiting for TAILORx and RxPONDER.

C. Perou, R. Gelber, M. Cheang, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up.

A. Goldhirsch, G. Viale, K. Price, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy benefit for 'ER-positive' breast cancer and contamination of Nonluminal subtypes-waiting for TAILORx and RxPONDER.

C. Perou, R. Gelber, M. Cheang, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A multi-center, randomized, prospective study evaluating the optimal radiation dose of definitive concurrent chemoradiation for inoperable esophageal squamous cell carcinoma.

Jun Ma, Ming Chen, Wanwei Wang, 2018 .

Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Updated safety analysis of trial BIG 1–98

A. Coates, B. Thürlimann, L. Mauriac, 2007 .

1414TiP Evaluating telisotuzumab vedotin in combination with osimertinib in patients with advanced non-small cell lung cancer: A phase I/Ib study cohort

D. Camidge, P. Komarnitsky, J. Goldman, 2020 .